A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutations

TAS-117 at the RP2D of 16 mg o.d. was tolerable, with a manageable safety profile. Clinical benefit, although durable, was only observed in a single patient with a germline PTEN mutation.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2025-12-30
DOI
https://doi.org/10.1016/j.esmoop.2025.105932
Primary Topic
PI3K/AKT/mTOR signaling in cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutations

T.W. Laetsch, S.P. Chawla, Y. He, M. Mina et al.
ESMO Open
PI3K/AKT/mTOR signaling in cancer
article

A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutations

T.W. Laetsch, S.P. Chawla, Y. He, M. Mina, A. Hervieu, P. Funchain, S. Delaloge, H.-T. Arkenau, V. Wacheck, K. Anthony, C.F. Singer, Y.R. Murciano-Goroff, J. Ródon
article en

Abstract

TAS-117 at the RP2D of 16 mg o.d. was tolerable, with a manageable safety profile. Clinical benefit, although durable, was only observed in a single patient with a germline PTEN mutation.

ESMO OpenVol. 11(1)
Twitter (United States) (US), Memorial Sloan Kettering Cancer Center (US), Children's Hospital of Philadelphia (US), The University of Texas MD Anderson Cancer Center (US), Sarah Cannon Research Institute (GB), Université Paris-Saclay (FR), Institut Gustave Roussy (FR), Comprehensive Cancer Center Vienna (AT), Centre Georges François Leclerc (FR), Sarcoma Oncology Center (US), Taiho Oncology (United States) (US), PTEN Hamartoma Tumor Syndrome Foundation (US), University of Pennsylvania (US)
Openalex Percentile: Top 35%
PI3K/AKT/mTOR signaling in cancer
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutations — T.W. Laetsch, S.P. Chawla, et al. · ESMO Open (2025) | TGRS Research Map | TGRS